Drugs in Dev. Cardiology/Vascular Diseases
Phase I/ Phase II
France 
Lead Product(s) : TOTUM•070
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
VALBIOTIS Receives US and European TOTUM-070 Patent for Reducing Hypercholesterolemia
Details : TOTUM-070 is a combination of plant extracts that contains neither phytosterols nor red yeast rice, designed by VALBIOTIS’ proprietary R&D platform based in Riom (63).
Product Name : Totum•070
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
September 14, 2020
Lead Product(s) : TOTUM•070
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TOTUM•070
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VALBIOTIS expects to start a Phase II clinical trial evaluating the effect of TOTUM-070 in reducing LDL-cholesterol, in mild to moderate hypercholesterolemic patients.
Product Name : Totum•070
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
April 16, 2020
Lead Product(s) : TOTUM•070
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
